An Efficacy and Safety Study of AG-221 (CC-90007) Versus Conventional Care Regimens in Older Subjects With Late Stage Acute Myeloid Leukemia Harboring an Isocitrate Dehydrogenase 2 Mutation

Phase 3

Completed

Conditions: Leukemia, Myeloid
Isocitrate Dehydrogenase

Interventions: Drug: AG-221
Other: BSC
Drug: Azacitidine
Drug: Low-dose cytarabine (LDAC)
Drug: Intermediate-dose cytarabine (IDAC)

Registration Number: NCT02577406

Lead Sponsor: Celgene

Brief Summary: This is an international, multicenter, open-label, randomized, Phase 3 study comparing the efficacy and safety of AG-221 versus conventional care regimens (CCRs) in subjects 60 years or older with acute myeloid leukemia (AML) refractory to or relapsed after second- or third-line AML therapy and positive for an isocitrate dehydrogenase (IDH2) mutation.

Detailed Description: Acute myeloid leukaemia (AML) is a form of cancer that is common in older patients. Mutations in the isocitrate dehydrogenase enzyme 2 (IDH2) have been found in approximately 15% of patients with AML.

The outcome of first line chemotherapy treatment is poor and many patients fail to attain complete remission (CR, ie refractory) or will eventually relapse. There is no single standard of care for relapsed or refractory AML. Since the prognosis is very poor there is a great need for new therapies.

Inhibition of the mutant IDH2 enzyme may represent a promising targeted therapy for AML. AG-221 is a small molecule inhibitor of the IDH2 enzyme, designed to preferentially target the mutant IDH2 variants. Data from the ongoing first-in-human study has shown AG-221 to be generally well tolerated and demonstrated CR in patients with IDH2 mutation positive relapsed or refractory AML.

The study purpose is to test the safety and efficacy of AG-221 compared with conventional care regimens (CCR), which include best supportive care (BSC) only, azacitidine plus BSC, low-dose cytarabine plus BSC or intermediate-dose cytarabine plus BSC, in patients with late stage AML refractory to or relapsed after second or third line therapy and positive for the IDH2 mutation. Patients will be randomly assigned to receive open-label tablets of AG-221 or one of the CCR on continuous 28-day treatment cycles. The trial duration is expected to be 78 months which includes 42 months enrollment, approximately 7 months treatment and a follow-up period.

Study procedures include: vital signs, physical exams, ECGs, ECHO, urine/blood samples, bone marrow aspirates and/or biopsies and peripheral blood to test for IDH2 and assess treatment response. Bone marrow, blood, cheek swab samples will be used for genetic tests.

This study is being sponsored by Celgene Corporation. Approximately 316 participants will take part in the study.

Recruitment & Eligibility

Status: COMPLETED

Sex: All

Target Recruitment: 319

Inclusion Criteria

Subjects must satisfy the following criteria to be enrolled in the study:

Subject is ≥ 60 years of age at the time of signing the ICF
Subject has primary (ie, de novo) or secondary (progression of MDS or myeloproliferative neoplasms ([MPN], or therapy-related) AML according to WHO classification (Appendix B)
Subject has received second- or third-line of AML therapy (see Appendix G for the definition of prior AML line; note that, for subjects having AML secondary to prior higher risk [Intermediate-2 or High risk according to the International Prognostic Scoring System] MDS treated with a hypomethylating agent [eg, azacitidine or decitabine], the hypomethylating therapy can be counted as a line if there is disease progression to AML during or shortly [eg, within 60 days] after the hypomethylating therapy.)
Subject has the following disease status:
1. Refractory to or relapsed after second- or third-line of intensive therapy for AML (eg, the "7 + 3" regimen):
  
  at least 5% leukemic blasts in bone marrow (the minimum number of treatment cycles of the intensive therapy is per the investigator's discretion); or
2. Refractory to or relapsed after second- or third-line low-intensity AML therapy (eg, LDAC, azacitidine or decitabine):
at least 5% leukemic blasts in bone marrow after at least 2 treatment cycles
Subject is eligible for and willing to receive the pre-selected CCR treatment option, according to the investigator's assessment (Note: Subjects with degenerative and toxic encephalopathies, especially after the use of methotrexate or treatment with ionizing radiation, should not receive cytarabine.)
Subject has Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2 (Appendix D)
Subject has IDH2 gene mutations tested centrally (using the "investigational use only"PCR assay, Abbott RealTime IDH2) in samples of bone marrow aspirate and peripheral blood, and confirmed positive in bone marrow aspirate and/or peripheral blood. (Note: in the event that the central laboratory result is delayed and precludes acute clinical management of a subject who has confirmed IDH2 gene mutation by local evaluation, the subject may be eligible for randomization with approval by the Medical Monitor.)
Subject has adequate organ function defined as:
- Aspartate aminotransferase (AST)/serum glutamic oxaloacetic transaminase (SGOT) and alanine aminotransferase (ALT)/serum glutamic pyruvic transaminase (SGPT) ≤ 3 x upper limit of normal (ULN), unless considered due to leukemic organ involvement, following review by the Medical Monitor; and
- Serum total bilirubin ≤ 1.5 x ULN, unless considered due to Gilbert's syndrome (eg, a gene mutation in UGT1A1) or leukemic organ involvement, following review by the Medical Monitor; and
- Creatinine clearance > 30 mL/min based on the Modification of Diet in Renal Disease (MDRD) glomerular filtration rate (GFR):
GFR (mL/min/1.73 m2) = 175 × (serum creatinine)-1.154 × (Age)-0.203 × (0.742 if female) × (1.212 if African American)
Females of childbearing potential (FCBP)* may participate, providing they meet the following conditions:
- Agree to practice true abstinence from sexual intercourse or to use highly effective contraceptive methods (eg, combined [containing estrogen and progestogen] or progestogen-only associated with inhibition of ovulation, oral, injectable, intravaginal, patch, or implantable hormonal contraceptive; bilateral tubal occlusion; intra-uterine device; intrauterine hormone-releasing system; or male partner sterilization [note that vasectomized partner is a highly effective birth control method provided that partner is the sole sexual partner of the FCBP trial participant and that the vasectomized partner has received medical assessment of the surgical success]) at screening and throughout the study, and for 4 months following the last study treatment (6 months following the last dose of cytarabine); and
- Have a negative serum β-subunit of human chorionic gonadotropin (β-hCG) pregnancy test (sensitivity of at least 25 mIU/mL) at screening; and
- Have a negative serum or urine (investigator's discretion under local regulations) β-hCG pregnancy test (sensitivity of at least 25 mIU/mL) within 72 hours prior to the start of study treatment in the Treatment Phase (note that the screening serum pregnancy test can be used as the test prior to the start of study treatment in the Treatment Phase if it is performed within the 72-hour timeframe).
Male subjects must agree to practice true abstinence from sexual intercourse or to the use of highly effective contraceptive methods (as described above) with non-pregnant female partners of childbearing potential at screening and throughout the course of the study, and should avoid conception with their partners during the course of the study and for 4 months following the last study treatment (6 months following the last dose of cytarabine; 6 months following the last dose of azacitidine in Canada)
Subject must understand and voluntarily sign an ICF prior to any study-related assessments/procedures being conducted
Subject is willing and able to adhere to the study visit schedule and other protocol requirements

Exclusion Criteria

The presence of any of the following will exclude a subject from enrollment:

Subject is suspected or proven to have acute promyelocytic leukemia based on morphology, immunophenotype, molecular assay, or karyotype
Subject has AML secondary to chronic myelogenous leukemia
Subject has received a targeted agent against an IDH2 mutation
Subject has received systemic anticancer therapy or radiotherapy < 14 days prior to the start of study treatment. Note that hydroxyurea is allowed prior to the start of study treatment for the control of leukocytosis (however, hydroxyurea should not be given within 72 hours prior to and after administration of azacitidine).
Subject has received non-cytotoxic or investigational agents < 14 days or 5 half-lives, whichever is longer, prior to the start of study treatment
Subject has undergone HSCT within 60 days prior to the start of study treatment, or on immunosuppressive therapy post HSCT at the time of screening, or with clinically significant graft-versus-host disease (GVHD). The use of a stable dose of oral steroid post-HSCT and/or topical steroids for ongoing skin GVHD is permitted.
Subject has persistent, clinically significant non-hematologic toxicities from prior therapies
Subject has or is suspected of having central nervous system (CNS) leukemia. Evaluation of cerebrospinal fluid is only required if CNS involvement by leukemia is suspected during screening.
Subject has active uncontrolled systemic fungal, bacterial, or viral infection (defined as ongoing signs/symptoms related to the infection without improvement despite appropriate antibiotics, antiviral therapy, and/or other treatment)
Subject has immediately life-threatening, severe complications of leukemia such as uncontrolled bleeding, pneumonia with hypoxia or shock, and/or disseminated intravascular coagulation
Subject has significant active cardiac disease within 6 months prior to the start of study treatment, including New York Heart Association (NYHA) class III or IV congestive heart failure (Appendix E); acute coronary syndrome (ACS); and/or stroke; or left ventricular ejection fraction (LVEF) < 40% by echocardiogram (ECHO) or multi-gated acquisition (MUGA) scan obtained within 28 days prior to the start of study treatment
Subject has prior history of malignancy, other than MDS, MPN or AML, unless the subject has been free of the disease for ≥ 1 year prior to the start of study treatment.

However, subjects with the following history/concurrent conditions are allowed:
- Basal or squamous cell carcinoma of the skin
- Carcinoma in situ of the cervix
- Carcinoma in situ of the breast
- Incidental histologic finding of prostate cancer (T1a or T1b using the tumor, node, metastasis clinical staging system)
Subject is known seropositive or active infection with human immunodeficiency virus (HIV), or active infection with hepatitis B virus (HBV) or hepatitis C virus (HCV)
Subject is known to have dysphagia, short-gut syndrome, gastroparesis, or other conditions that limit the ingestion or gastrointestinal absorption of drugs administered orally
Subjects has uncontrolled hypertension (systolic blood pressure [BP] > 180 mmHg or diastolic BP > 100 mmHg)
Subject is a pregnant or lactating female
Subject has known or suspected to have hypersensitivity to any of the components of study treatment
Subject is taking those medications (listed in Section 8.2) that are known to prolong QT interval unless the subject can be transferred to other medications at least 5 half-lives prior to the start of study treatment
Subject has QTc interval (ie, Fridericia's correction [QTcF]) ≥ 450 ms or other factors that increase the risk of QT prolongation or arrhythmic events (eg, heart failure, hypokalemia, family history of long QT interval syndrome) at screening
Subject is taking the following sensitive CYP substrate medications that have a narrow therapeutic range are excluded from the study unless the subject can be transferred to other medications at least 5 half-lives prior to the start of study treatment: paclitaxel and docetaxel (CYP2C8), phenytoin (CYP2C9), S-mephenytoin (CYP2C19), thioridazine (CYP2D6), theophylline, and tizanidine (CYP1A2)
Subject is taking the breast cancer resistance protein (BCRP) transporter-sensitive substrate rosuvastatin should be excluded from the study unless the subject can be transferred to other medications at least 5 half-lives prior to the start of study treatment
Subject has any significant medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from participating in the study
Subject has any condition including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study
Subject has any condition that confounds the ability to interpret data from the study

Study & Design

Study Type: INTERVENTIONAL

Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Conventional care regimen (CCR)	Low-dose cytarabine (LDAC)	Continuous 28-day cycles of BSC only, azacitidine subcutaneously (SC) plus BSC, low-dose cytarabine (LDAC) SC plus BSC, or intermediate-dose cytarabine (IDAC) intravenously (IV) plus BSC. Subjects will be assigned by the investigator to one of the CCR treatment options based on the investigator's assessment of subjects' eligibility.
Conventional care regimen (CCR)	Intermediate-dose cytarabine (IDAC)	Continuous 28-day cycles of BSC only, azacitidine subcutaneously (SC) plus BSC, low-dose cytarabine (LDAC) SC plus BSC, or intermediate-dose cytarabine (IDAC) intravenously (IV) plus BSC. Subjects will be assigned by the investigator to one of the CCR treatment options based on the investigator's assessment of subjects' eligibility.
AG-221 plus Best supportive care (BSC)	AG-221	Continuous 28-day cycles of AG 221 100 mg orally (PO) once a day (QD) for 28 days, plus BSC.
AG-221 plus Best supportive care (BSC)	BSC	Continuous 28-day cycles of AG 221 100 mg orally (PO) once a day (QD) for 28 days, plus BSC.
Conventional care regimen (CCR)	BSC	Continuous 28-day cycles of BSC only, azacitidine subcutaneously (SC) plus BSC, low-dose cytarabine (LDAC) SC plus BSC, or intermediate-dose cytarabine (IDAC) intravenously (IV) plus BSC. Subjects will be assigned by the investigator to one of the CCR treatment options based on the investigator's assessment of subjects' eligibility.
Conventional care regimen (CCR)	Azacitidine	Continuous 28-day cycles of BSC only, azacitidine subcutaneously (SC) plus BSC, low-dose cytarabine (LDAC) SC plus BSC, or intermediate-dose cytarabine (IDAC) intravenously (IV) plus BSC. Subjects will be assigned by the investigator to one of the CCR treatment options based on the investigator's assessment of subjects' eligibility.

Primary Outcome Measures

Name	Time	Method
Overall Survival (OS)	From randomization to death due to any cause (up to approximately 49 months)	The time between randomization and death from any cause. Participants who drop-out or are alive at the end of trial will have their OS times censored at the time of last contact, as appropriate.

Secondary Outcome Measures

Name	Time	Method
Overall Response Rate	From randomization up to study completion (approximately 78 months)	Number of participants with MLFS + CR + CRi + CRp + PR according to modified International Working Group Acute Myeloid Leukemia (IWG AML) response criteria. Complete response (CR) and morphologic leukemia-free state (MLFS) are defined as \<5% blasts in a BM aspirate sample with marrow spicules and a count of ≥200 nucleated cells. There should be no blasts with Auer rods and no extramedullary disease. CR must also include: absolute neutrophil count (ANC) ≥1,000/μL, Platelet count ≥100,000/μL, and independent of red cell transfusions for ≥1 week before each response assessment. Complete remission with incomplete neutrophil recovery (CRi) is all criteria of CR except ANC. Complete remission with incomplete platelet recovery (CRp) is all criteria of CR except platelet count. Partial remission (PR) is defined as all hematologic criteria of CR with a \>50% decrease in the percentage of BM blasts to 5% to 25%. (\<5% considered if Auer rods are present).
Event-Free Survival	From randomization up to study completion (approximately 78 months)	Time from randomization to documented morphologic relapse after complete remission/complete remission with incomplete neutrophil recovery/complete remission with incomplete platelet recovery (CR/CRi/CRp), progressive disease (PD) or death from any cause, whichever occurs first. Morphologic Relapse after CR/CRi/CRp is defined as either reappearance of ≥ 5% blasts in the BM not attributable to any other cause or the development of extramedullary disease. PD is defined as a \> 50% increase of BM blast count percentage from baseline to ≥ 20% for participants with 5 to 70% BM blasts at baseline or a doubling of absolute blast count in peripheral blood from baseline to ≥ 10 x 109/L (10,000/μL) for participants with \> 70% BM blasts at baseline or the development of new extramedullary disease.
Duration of Response	From randomization up to study completion (approximately 78 months)	Time from first documented MLFS/CR/CRi/CRp/PR to documented morphologic relapse after CR/CRi/CRp/ PD or death due to any cause, whichever occurs first. CR and MLFS are defined as \<5% blasts in a BM aspirate sample with marrow spicules + a count of ≥200 nucleated cells with no blasts with Auer rods + no extramedullary disease. CR must also include: ANC ≥ 1,000/μL, Platelet count ≥100,000/μL, + independent of red cell transfusions for ≥1 week before assessment. CRi is all criteria of CR except ANC. CRp is all criteria of CR except platelet count. PR is defined as all hematologic criteria of CR with \>50% decrease in BM blasts to 5%-25%. Relapse after CR/CRi/CRp is defined as reappearance of ≥ 5% blasts in the BM not attributable to other cause or development of extramedullary disease. PD is defined as \> 50% increase of BM blast count from baseline to ≥ 20% or a doubling of absolute blast count in peripheral blood from baseline to ≥ 10,000/μL or development of new extramedullary disease.
Time to Response	From randomization to to first documented MLFS/CR/CRi/CRp/PR (up to approximately 49 months)	Time from randomization to first documented MLFS/CR/CRi/CRp/PR. Complete remission (CR) and morphologic leukemia-free state (MLFS) are defined as \<5% blasts in a BM aspirate sample with marrow spicules and a count of ≥200 nucleated cells. There should be no blasts with Auer rods and no extramedullary disease. CR must also include the following conditions: absolute neutrophil count (ANC) ≥1,000/μL, Platelet count ≥100,000/μL, and independent of red cell transfusions for ≥1 week before each response assessment. Complete remission with incomplete neutrophil recovery (CRi) is all criteria of CR except ANC. Complete remission with incomplete platelet recovery (CRp) is all criteria of CR except platelet count. partial remission (PR) is defined as all hematologic criteria of CR with a \>50% decrease in the percentage of BM blasts to 5% to 25%. (\<5% considered if Auer rods are present).
Treatment Mortality at 30 Days	From first dose to 30 days after first dose	The number of participant deaths from any cause within 30 days of initiation of study treatment.
Treatment Mortality at 60 Days	From first dose to 60 days after first dose	The number of participant deaths from any cause within 60 days of initiation of study treatment.
One-Year Survival Rate	From randomization up to 1 year post (approximately 12 months)	The proportion of participants alive at 1 year after randomization
Overall Remission Rate	From randomization up to approximately 49 months	The number of participants with CR + CRi + CRp according to modified International Working Group Acute Myeloid Leukemia (IWG AML) response criteria. Complete remission (CR) is defined as \<5% blasts in a BM aspirate sample with marrow spicules and a count of ≥200 nucleated cells. There should be no blasts with Auer rods and no extramedullary disease. CR must also include the following conditions: absolute neutrophil count (ANC) ≥1,000/μL, Platelet count ≥100,000/μL, and independent of red cell transfusions for ≥1 week before each response assessment. Complete remission with incomplete neutrophil recovery (CRi) is all criteria of CR except ANC. Complete remission with incomplete platelet recovery (CRp) is all criteria of CR except platelet count.
Complete Remission Rate	From randomization up to approximately 49 months	The number of participants with morphologic complete remission (CR) according to modified International Working Group Acute Myeloid Leukemia Response Criteria (IWG AML). CR is defined as less than 5% blasts in a BM aspirate sample with marrow spicules and with a count of at least 200 nucleated cells. There should be no blasts with Auer rods and absence of extramedullary disease; plus the following conditions: absolute neutrophil count (ANC) ≥1,000/μL, Platelet count ≥100,000/μL, and independent of red cell transfusions for ≥1 week before each response assessment.
Hematologic Improvement Rate	From randomization up to approximately 49 months	The number of participants with hematologic improvement neutrophil response (HI-N) + hematologic improvement platelet response (HI-P) + hematologic improvement erythroid response (HI-E) according to the International Working Group for Myelodysplastic Syndromes for Hematologic Improvement (IWG MDS HI) criteria. HI-E is defined as a hemoglobin increase by ≥ 1.5 g/dL and a relevant reduction in units of RBC transfusions by an absolute number of at least 4 RBC transfusions/8 week compared with the pretreatment transfusion number in the previous 8 week. HI-P is defined as an absolute increase of ≥ 30 X 10\^9/L for participants starting with \> 20 X and an increase from \< 20 X 10\^9/L to \> 20 X 10\^9/L and by at least 100%. HI-N is defined as At least 100% increase and an absolute increase \> 0.5 X 10\^9/L.
The Number of Participants That Underwent Hematopoietic Stem Cell Transplantation (HSCT)	From randomization up to approximately 49 months	The number of participants that underwent hematopoietic stem cell transplantation during the study.
Time to Treatment Failure	From randomization to discontinuation of study treatment due to any cause (up to approximately 49 months)	Time from randomization to discontinuation of study treatment due to any cause
The Number of Participants Experiencing Adverse Events (AEs)	From randomization up to study completion (approximately 78 months)	The number of participants experiencing different types of adverse events (AE). An AE is any noxious, unintended, or untoward medical occurrence that may appear or worsen in a participant during the course of a study. A Serious Adverse Event (SAE) is any AE occurring at any dose that: results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or constitutes an important medical event. All AEs were coded using the MedDRA Version 22.0. Adverse events were analyzed in terms of treatment-emergent AEs (TEAEs). A treatment-related TEAE was defined as a TEAE that was suspected by the investigator to be related to study treatment. The severity was graded by the study personnel based on NCI National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03.
The Percent of Participants Experiencing Clinically Significant Laboratory Abnormalities - Serum Chemistry	From first dose up to approximately 49 months	The percent of participants with clinically significant serum chemistry laboratory abnormalities. A clinically significant laboratory abnormality is defined as meeting Grade 3 or Grade 4 criteria according to the Common Terminology Criteria for Adverse Events (CTCAE). Grade 3 is defined as severe or medically significant but not immediately life threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care. Grade 4 is defined as life-threatening consequences; urgent intervention indicated. The chemistry panel includes sodium, potassium, calcium, magnesium, chloride, phosphorus, CO2, bicarbonate, blood urea nitrogen (BUN), creatinine, glucose, albumin, total protein, alkaline phosphatase (ALP), bilirubin (total and direct), uric acid, lactate dehydrogenase (LDH), AST/SGOT, ALT/SGPT, gamma glutamyl transpeptidase (GGT), amylase and lipase.
The Percent of Participants Experiencing Clinically Significant Laboratory Abnormalities - Hematology	From first dose up to approximately 49 months	The percent of participants with clinically significant hematology laboratory abnormalities. A clinically significant laboratory abnormality is defined as meeting Grade 3 or Grade 4 criteria according to the Common Terminology Criteria for Adverse Events (CTCAE). Grade 3 is defined as severe or medically significant but not immediately life threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care. Grade 4 is defined as life-threatening consequences; urgent intervention indicated. The hematology panel includes complete blood count (CBC) with differential, including red blood cell (RBC) count, hemoglobin, hematocrit, mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin concentration (MCHC), white blood cell (WBC) count (with differential), absolute neutrophil count (ANC) and platelet count.
The Percent of Participants Experiencing Clinically Significant Vital Sign Abnormalities	From first dose up to approximately 49 months	The percent of participants with clinically significant vital sign abnormalities including weight, temperature, blood pressure, pulse rate, and respiratory rate.
The Percentage of Participants Experiencing Clinically Significant Electrocardiogram (ECG) Abnormalities	From first dose up to approximately 49 months	The percent of participants with clinically significant ECG abnormalities. 12-lead ECG was assessed by a physician trained in ECG interpretation. Intervals including PR, QRS, QT and RR were collected, as well as heart rate and rhythm.
Change From Baseline in the European Organization for Research and Treatment of Cancer Quality-of-Life Questionnaire (EORTC QLQ-C30)	From baseline to cycle 2 day 1 (up to approximately 1 month)	The change from baseline in the EORTC QLQ-C30 questionnaire. The EORTC QLQ-C30 is composed of 30 items that address general physical symptoms, physical functioning, fatigue and malaise, and social and emotional functioning. Subscale scores are transformed to a 0 to 100 scale, with higher scores on functional scales indicating better function and higher scores on symptom scales indicating worse symptoms. A change of at least 10 points on the standardized domain scores was required for it to be considered meaningful. Results obtained just prior to the start of study treatment on Day 1 of Cycle 1 will serve as the baseline values. If not available, the most recent screening results prior to the start of study treatment on Day 1 of Cycle 1 will be considered the baseline values.
Change From Baseline in EQ-5D-5L Health Utility Index	From baseline up to cycle 2 day 1 (up to approximately 1 month)	The European Quality of Life 5D-5L Scale (EQ-5D-5L) assesses general health-related quality of life. Health is defined in 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. Responses are coded so that a '1' indicates no problem, and '5' indicates the most serious problem. The responses for the 5 dimensions are combined in a 5-digit number. These health states are converted to a single index value using the crosswalk method to the EQ-5D-3L value set from the United Kingdom (UK). The EQ-5D-3L health utility index based on the UK population weights range from -0.594 to 1.0 with higher scores indicating higher health utility. Baseline results are obtained just prior to the start of study treatment on Day 1 of Cycle 1 and will serve as the baseline values.

Trial Locations

Locations (93): Local Institution - 874
🇹🇷
Denizli, Turkey
Local Institution - 875
🇹🇷
Gaziantep, Turkey
Local Institution - 904
🇦🇺
Adelaide, South Australia, Australia
Local Institution - 906
🇦🇺
East Melbourne, Australia
Local Institution - 905
🇦🇺
Melbourne, Australia
Local Institution - 803
🇦🇹
Linz, Austria
Local Institution - 811
🇧🇪
Yvoir, Belgium
Local Institution - 121
🇺🇸
Miami, Florida, United States
University of Florida Health Cancer Center at Orlando Health
🇺🇸
Orlando, Florida, United States
Local Institution - 111
🇺🇸
Chicago, Illinois, United States
John Theurer Cancer Center at Hackensack University Medical Center
🇺🇸
Hackensack, New Jersey, United States
Montefiore Medical Center Albert Einstein Cancer Center
🇺🇸
Bronx, New York, United States
Roswell Park Cancer Institute
🇺🇸
Buffalo, New York, United States
Local Institution - 128
🇺🇸
New York, New York, United States
Strong Health System
🇺🇸
Rochester, New York, United States
Duke University Medical Center
🇺🇸
Durham, North Carolina, United States
University Hospitals Cleveland Medical Center
🇺🇸
Cleveland, Ohio, United States
Local Institution - 104
🇺🇸
Greenville, South Carolina, United States
Baylor Sammons Cancer Center
🇺🇸
Dallas, Texas, United States
Local Institution - 901
🇦🇺
Concord, New South Wales, Australia
Local Institution - 252
🇧🇷
Porto Alegre, RS, Rio Grande Do Sul, Brazil
Local Institution - 250
🇧🇷
Porto Alegre, Rio Grande Do Sul, Brazil
Local Institution - 251
🇧🇷
Jau, Brazil
Local Institution - 253
🇧🇷
Rio de Janeiro, Brazil
Local Institution - 254
🇧🇷
São Paulo, Brazil
Local Institution - 202
🇨🇦
Edmonton, Alberta, Canada
Local Institution - 203
🇨🇦
Winnipeg, Manitoba, Canada
Local Institution - 201
🇨🇦
Toronto, Ontario, Canada
Local Institution - 204
🇨🇦
Montreal, Quebec, Canada
Local Institution - 885
🇨🇳
Beijing, China
Local Institution - 884
🇨🇳
Beijing, China
Local Institution - 892
🇨🇳
Beijing, China
Local Institution - 888
🇨🇳
Chengdu, Sichuan, China
Local Institution - 882
🇨🇳
Fuzhou, China
Local Institution - 881
🇨🇳
Guangzhou, Guangdong, China
Local Institution - 883
🇨🇳
Hangzhou City, China
Local Institution - 887
🇨🇳
Shanghai, China
Local Institution - 891
🇨🇳
Shanghai, China
Local Institution - 889
🇨🇳
Zhengzhou, China
Local Institution - 822
🇨🇿
Praha, Czechia
Local Institution - 834
🇩🇰
Aalborg, Denmark
Local Institution - 833
🇩🇰
Arhus C, Denmark
Local Institution - 831
🇩🇰
Copenhagen, Denmark
Local Institution - 832
🇩🇰
Odense, Denmark
Local Institution - 606
🇫🇷
Angers, France
Local Institution - 605
🇫🇷
BOBIGNY Cedex, France
Local Institution - 602
🇫🇷
Lille, France
Local Institution - 612
🇫🇷
Marseille cedex, France
Local Institution - 601
🇫🇷
Nantes, France
Local Institution - 607
🇫🇷
Pessac, France
Local Institution - 611
🇫🇷
Pierre-Bénite Cedex, France
Local Institution - 609
🇫🇷
Toulouse Cedex, France
Local Institution - 610
🇫🇷
Versailles, France
Local Institution - 604
🇫🇷
Villejuif CEDEX, France
Local Institution - 403
🇩🇪
Dresden, Germany
Local Institution - 413
🇩🇪
Essen, Germany
Local Institution - 406
🇩🇪
Frankfurt, Germany
Local Institution - 401
🇩🇪
Hannover, Germany
Local Institution - 412
🇩🇪
Leipzig, Germany
Local Institution - 402
🇩🇪
Mainz, Germany
Local Institution - 409
🇩🇪
München, Germany
Local Institution - 407
🇩🇪
Ulm, Germany
Local Institution - 305
🇮🇹
Bologna, Italy
Local Institution - 304
🇮🇹
Brescia, Italy
Local Institution - 302
🇮🇹
Firenze, Italy
Local Institution - 301
🇮🇹
Naples, Italy
Local Institution - 306
🇮🇹
Palermo, Italy
Local Institution - 303
🇮🇹
Reggio Calabria, Italy
Local Institution - 307
🇮🇹
Roma, Italy
Local Institution - 953
🇰🇷
Hwasun-gun, Korea, Republic of
Local Institution - 952
🇰🇷
Seoul, Korea, Republic of
Local Institution - 861
🇷🇺
Krasnoyarsk, Russian Federation
Local Institution - 864
🇷🇺
Moscow, Russian Federation
Local Institution - 863
🇷🇺
Moscow, Russian Federation
Local Institution - 862
🇷🇺
Saint-Petersburg, Russian Federation
Local Institution - 701
🇪🇸
Oviedo, Asturias, Spain
Local Institution - 706
🇪🇸
Avda, Campanar 21, Spain
Local Institution - 708
🇪🇸
Barcelona, Spain
Local Institution - 704
🇪🇸
Barcelona, Spain
Local Institution - 709
🇪🇸
Salamanca, Spain
Local Institution - 702
🇪🇸
Sevilla, Spain
Local Institution - 942
🇨🇳
Taichung, Northern Dist., Taiwan
Local Institution - 940
🇨🇳
Taipei, Zhongzheng Dist., Taiwan
Local Institution - 941
🇨🇳
Taoyuan, Taiwan
Local Institution - 873
🇹🇷
Ankara, Turkey
Local Institution - 872
🇹🇷
Ankara, Turkey
Local Institution - 871
🇹🇷
Ankara, Turkey
Local Institution - 503
🇬🇧
Nottingham, Nottinghamshire, United Kingdom
Local Institution - 501
🇬🇧
London, United Kingdom
Local Institution - 507
🇬🇧
London, United Kingdom
Local Institution - 502
🇬🇧
Manchester Withington, United Kingdom
Local Institution - 510
🇬🇧
Oxford, United Kingdom
Local Institution - 509
🇬🇧
Sutton (Surrey), United Kingdom